Oral insulin (antigen-specific immunotherapy)

Oral insulin is one of the oldest ideas in T1D prevention with one of the most stubborn track records: give insulin by mouth not to lower glucose, but as an antigen — a way to teach the immune system to tolerate the very protein it attacks first. It is the cleanest test of "antigen-specific immunotherapy": calm the attack without the broad immune suppression that other approaches carry.

Screening: who is even eligible

You can only offer a prevention therapy to people you've found. T1D is now understood as a staged disease: stage 1 is two or more islet autoantibodies with normal glucose, stage 2 adds dysglycemia, and stage 3 is the clinical diabetes everyone recognizes.¹ That staging matters because the risk is steep and predictable: children who develop multiple islet autoantibodies have roughly a 70% chance of clinical diabetes within 10 years (and near-certainty over a lifetime), versus about 15% for a single antibody.² Two tiers of screening feed the trials: autoantibody screening in older children (the basis of programs like Fr1da, which showed population-level capillary-blood screening of young children is feasible and can catch disease before dangerous diabetic ketoacidosis at onset),³ and genetic screening of newborns to find the ~1% of infants whose gene profile gives a >10% risk of autoimmunity — the entry point for infant prevention.⁴

Therapy: mechanism, trials, and the honest result

Mechanism: swallowed insulin is broken down before it can affect blood sugar, so it acts purely as an antigen presented to gut-associated immune tissue, aiming to expand regulatory ("calming") T cells. A dose-finding study (Pre-POInT) showed this is real and dose-dependent: 67.5 mg/day produced a tolerogenic immune response in 5 of 6 children, with no hypoglycemia and no new autoantibodies — establishing both a dose and a clean safety profile.⁵

But the prevention trials have been neutral. The original DPT-1 oral insulin trial (relatives, stage 1–2) found no overall delay, with only a hypothesis-generating signal in people with high insulin-autoantibody titers.⁶ TrialNet then ran a confirmatory trial (NCT00419562): again no effect in the main group (hazard ratio 0.87), but a striking delay in the pre-specified high-risk "secondary stratum 1" (HR 0.45).⁷ Most recently, GPPAD's POInT primary-prevention trial (NCT03364868) gave high-dose oral insulin to 1,050 genetically at-risk infants starting at 4–7 months — the boldest test yet. The headline was again neutral: 10% of the insulin group vs 9% of placebo developed multiple autoantibodies or diabetes (HR 1.12).⁸ The twist that keeps the field alive: a gene–treatment interaction — children with insulin-gene (INS) risk variants were protected from progression, while those with non-risk variants fared slightly worse — hinting that the average result buried opposite effects in different people.⁹

Safety and stages: across every trial, in healthy children and infants, oral insulin has been remarkably safe — no hypoglycemia, adverse events matching placebo.⁷⁸ That safety is exactly why it remains attractive for the youngest, healthiest candidates. Access: it is not approved anywhere for prevention and exists only inside research studies; contrast teplizumab, the one approved stage-2 therapy.¹

What's coming

POInT children are being followed to age 12 to see whether the genotype-defined protection becomes a real delay in diabetes, and the consortium is explicitly pivoting toward personalized prevention — matching oral insulin (and dose) to the children whose genetics predict benefit, rather than treating everyone the same.⁹ If that pharmacogenetic story holds, a cheap, oral, side-effect-free therapy could re-emerge as a precision tool. For now, the honest verdict is: a safe idea, repeatedly neutral overall, kept alive by credible subgroup signals.

References

1. Insel RA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care (2015). https://doi.org/10.2337/dc15-1419 ↩ ↩²

2. Ziegler AG, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA (2013). https://doi.org/10.1001/jama.2013.6285 ↩

3. Raab J, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open (2016). https://doi.org/10.1136/bmjopen-2016-011144 ↩

4. Ziegler AG, et al. (POInT). Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial. Lancet (2025). https://doi.org/10.1016/S0140-6736%2825%2901726-X ↩

5. Bonifacio E, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA (2015). https://doi.org/10.1001/jama.2015.2928 ↩

6. Skyler JS, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005). https://doi.org/10.2337/diacare.28.5.1068 ↩

7. Krischer JP, et al. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial (TrialNet, NCT00419562). JAMA (2017). https://doi.org/10.1001/jama.2017.17070 ↩ ↩²

8. GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial), NCT03364868. ClinicalTrials.gov (2025). https://clinicaltrials.gov/api/v2/studies/NCT03364868 ↩ ↩²

9. Helmholtz Munich / TUM. New milestone towards personalized prevention of type 1 diabetes (POInT results and next steps). Helmholtz Munich newsroom (2025). https://www.helmholtz-munich.de/en/newsroom/news-all/artikel/new-milestone-towards-personalized-prevention-of-type-1-diabetes ↩ ↩²